- Home
- ML vs COLL Comparison
ML vs COLL Comparison
Compare ML & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ML
- COLL
- Stock Information
- Founded
- ML 2013
- COLL 2002
- Country
- ML United States
- COLL United States
- Employees
- ML N/A
- COLL N/A
- Industry
- ML Retail: Computer Software & Peripheral Equipment
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- ML Technology
- COLL Health Care
- Exchange
- ML Nasdaq
- COLL Nasdaq
- Market Cap
- ML 969.9M
- COLL 1.0B
- IPO Year
- ML N/A
- COLL 2015
- Fundamental
- Price
- ML $85.77
- COLL $29.13
- Analyst Decision
- ML Buy
- COLL Strong Buy
- Analyst Count
- ML 7
- COLL 5
- Target Price
- ML $100.00
- COLL $43.60
- AVG Volume (30 Days)
- ML 152.9K
- COLL 304.0K
- Earning Date
- ML 03-06-2025
- COLL 02-27-2025
- Dividend Yield
- ML N/A
- COLL N/A
- EPS Growth
- ML N/A
- COLL 757.11
- EPS
- ML 0.28
- COLL 2.16
- Revenue
- ML $500,281,000.00
- COLL $599,245,000.00
- Revenue This Year
- ML $30.79
- COLL $13.25
- Revenue Next Year
- ML $22.93
- COLL $17.67
- P/E Ratio
- ML $298.50
- COLL $13.47
- Revenue Growth
- ML 23.40
- COLL 9.62
- 52 Week Low
- ML $36.65
- COLL $28.39
- 52 Week High
- ML $106.82
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- ML 44.25
- COLL 37.61
- Support Level
- ML $85.73
- COLL $29.39
- Resistance Level
- ML $87.54
- COLL $30.39
- Average True Range (ATR)
- ML 0.87
- COLL 1.00
- MACD
- ML -0.26
- COLL -0.24
- Stochastic Oscillator
- ML 1.52
- COLL 11.04
About ML MoneyLion Inc.
MoneyLion Inc is a mobile banking and financial membership platform that empowers people to take control of their finances. It is a full-service digital platform to deliver mobile banking, lending, and investment solutions. The company offers a personalized, all-in-one, digital financial platform that provides convenient, low-cost access to banking, borrowing, and investing solutions tailored for its customers, rooted in data, and delivered through its proprietary technology platform.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.